Cargando…
Optimising the IgG‐degrading enzyme treatment regimen for enhanced adeno‐associated virus transduction in the presence of neutralising antibodies
OBJECTIVE: Pre‐existing neutralising antibodies (NAbs) to adeno‐associated viruses (AAVs) remain an impediment for systemically administered AAV‐mediated gene therapy treatment in many patients, and various strategies are under investigation to overcome this limitation. Here, IgG‐degrading enzymes (...
Autores principales: | Ros‐Gañán, Irene, Hommel, Mirja, Trigueros‐Motos, Laia, Tamarit, Blanche, Rodríguez‐García, Estefanía, Salas, David, Pérez, Guiomar, Douar, Anne, Combal, Jean Philippe, Benichou, Bernard, Ferrer, Veronica, González‐Aseguinolaza, Gloria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867416/ https://www.ncbi.nlm.nih.gov/pubmed/35228870 http://dx.doi.org/10.1002/cti2.1375 |
Ejemplares similares
-
Use of an adeno‐associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
por: Kaiser, Robert A., et al.
Publicado: (2021) -
High value of (64)Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson’s disease
por: Murillo, Oihana, et al.
Publicado: (2022) -
Chemical modification of the adeno-associated virus capsid to improve gene delivery
por: Mével, Mathieu, et al.
Publicado: (2019) -
Adeno-Associated Viral Vectors Serotype 8 for Cell-Specific Delivery of Therapeutic Genes in the Central Nervous System
por: Pignataro, Diego, et al.
Publicado: (2017) -
Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model
por: Weber, Nicholas D., et al.
Publicado: (2019)